BWV-301

**BWV-301** was a preclinical prophylactic vaccine candidate developed by Blue Water Vaccines for prevention of gastroenteritis caused by norovirus or rotavirus. It used Cincinnati Children's Hospital Medical Center's norovirus shell-and-protrusion virus-like particle platform, a nanoparticle-based platform intended to display pathogen antigens and elicit protective adaptive immune responses. Public company materials identified BWV-301 specifically as the norovirus/rotavirus gastroenteritis program; the pneumococcal acute-otitis-media candidate licensed from St. Jude was BWV-201, not BWV-301. ([ir.onconetix.com](https://ir.onconetix.com/blue-water-vaccines-announces-publication-in-nano-research-supporting-novel-sp-vaccine-platform-versatility/)) Blue Water Biotech subsequently reported that it was deprioritizing its vaccine portfolio in October 2023 while transitioning toward an oncology-focused business, and its successor company is now Onconetix. ([fiercebiotech.com](https://www.fiercebiotech.com/biotech/blue-water-changes-tides-again-dropping-all-vaccine-programs-and-6-approved-drugs))

Other names

norovirus shell and protrusion nanoparticle vaccine platformnorovirus S&P virus-like particle vaccine platform